Here’s what’s in store for you in today’s issue:
🍄 How to avoid adverse reactions to psychedelics
🍄 LSD found to reduce anxiety for 4 months
🍄 How ketamine affects the brain over time
🍄 A study to understand neurodiversity
🍄 And more.
Listen now on YouTube, Spotify, or Apple
MAPS announced that its Phase 3 MDMA trial for PTSD is now fully enrolled at 13 sites across the United States and Israel.
The organization took equity initiatives to ensure that BIPOC and LGBTQ+ individuals are represented in the study, as these individuals are more likely to have PTSD (yet less likely to be diagnosed or have reasonable access to treatment).
A survey of over 9,200 psilocybin mushroom users found that only 0.2% have sought emergency medical treatment following use.
The most common reported reasons for these adverse experiences were:
Additionally, those in the emergency care-seeking group were significantly younger than the group that didn’t seek care, with a median age of 19 compared to 23.
Keep this in mind if you’re considering trying psilocybin!
MindMed’s collaborators at University Hospital Basel studied the effect of two high doses of LSD (200μg) on patients with anxiety disorders.
They found that 65% of subjects had significant reductions in anxiety scores for 16 weeks after the treatments.
Like many other studies have found, mystical experiences were significantly correlated with long-term therapeutic benefits.
COMPASS Pathways (CMPS) is funding a psilocybin study to better understand the brain science of neurodiversity.
Using brain imaging and behavioural tasks, researchers will investigate how psilocybin affects the serotonin brain networks in autistic adults compared to non-autistic adults.
The goal is to understand the unique brain mechanisms associated with autism to provide “better tailored choices” to autistic people.
CMPS shares spiked 11% yesterday after the company announced Q1 financial results, including $21.2M net loss and $243.7M in cash.
Wesana Health (WESA) is considering selling all assets related to client care (like its network of ketamine clinics and mental health software) to focus solely on drug development.
Psycheceutical Inc., a subsidiary of Psycheceutical Bioscience (BWVI), announced that OG Shark Tank investor Kevin Harrington is joining the company as an investor and strategic advisor.
FSD Pharma (HUGE) sold its assets related to cannabis processing to focus on biotech. The C$16.4M in proceeds give the company enough capital to support operations through 2025.
PharmAla Biotech (MDMA) signed a distribution agreement with CCrest Laboratories, making its MDMA available to both international and domestic customers.
At least 17 activists were arrested for protesting at the DEA headquarters. The purpose of the protest was to raise awareness about the DEA’s obstruction of access to psilocybin therapy, which should be legal for terminally ill patients through the Right to Try (RTT) laws.
“There is urgent need for the DEA to accommodate RTT and enable access (to psilocybin). This demonstration shines the bright light of public concern and outrage on this agency’s conduct,” says Kathryn Tucker, the attorney behind the litigation.